**Table B5. Oral Hypoglycemic Agents: Data Abstraction: Study Funder and Conflicts of Interest**

|   |   | **Study characteristics, from the publication** |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Journal** | **Study funder** | **Percentage of authors employed by pharmaceutical industry**  | **Percentage of authors with COI from industry** | **What company makes intervention drug?** | **What company makes comparator drug?** | **Was there any assistance authoring the publication?** | **Did the publication indicate that the trial was registered?** |
| Aschner 2010 | Diabetes, Obesity and Metabolism | Merck & Co., Inc. | 6/7 (85%) | 1/1 (100%) | Sitagliptin: Merck & Co., Inc | Metformin: genericFortamet: Shionogi Pharma, Inc. | Yes | Yes |
| Bakris 2006 | Journal of Hypertension | GlaxoSmithKline | 5/7 (71%) | 1/2 (50%) | Rosiglitazone: GlaxoSmithKline (Avandia) and metformin: generic | Metformin: genericGlyburide: generic and sanofi-aventis U.S. LLC (DiaBeta) | Yes | No |
| Bunck 2009 | Diabetes Care | The study was sponsored by Amylin Pharmaceuticals and Eli Lilly and Company | 5/12 (42%) | 6/7 (86%) | Exenatide: Amylin and Eli Lilly | Insulin Glargine: sanofi-aventis (Lantus) | NR | Yes |
| Defronzo 2009 | Diabetes Care | Bristol-Myers Squibb and AstraZeneca | 3/7 (43%) | 4/4 (100%) | Saxagliptin: Bristol-Myers Squibb (Onglyza) | Metformin: generic | Yes | Yes |
| Defronzo 2010 | Diabetes Care | NR | 4/6 (67%) | 2/2 (100%) | Exenatide: Amylin and Eli Lilly | Rosiglitazone: GlaxoSmithKline  | NR | Yes |
| Garber 2009 | The Lancet | Novo Nordisk A/S | 2/9 (22%) | 4/7 (57%) | Liraglutide: Novo Nordisk (Victoza) | Glimepiride: generic | Yes | Yes |
| Goldberg 2005 | Diabetes Care | Eli Lilly and Takeda Pharmaceuticals | 6/10 (60%) | 0/4 (0%) | Pioglitazone: Takeda Pharmaceuticals | Rosiglitazone: GlaxoSmithKline (Avandia) | No | No |
| Goldstein 2007; Williams-Herman 2009 | Clinical Care / Education / Nutrition / Psychosocial Research | Merck & Co., Inc. | Goldstein: 3/5 (60%)Williams-Herman: 8/8 (100%)  | Goldstein: 2/2 (100%)Williams-Herman: NA | Sitagliptin: Merck and Co., Inc. | Metformin: generic | Goldstein: YesWilliams-Herman: NR | Yes |
| Gupta 2009 | Diabetes, Obesity and Metabolism | Takeda Pharmaceuticals | 0/4 (0%) | 2/4 (50%) | Pioglitazone: Takeda Pharmaceuticals | Metformin: generic | NR | Yes |
| Hamann 2008 | Exp Clin Endocrinol Diabetes | NR (clearly GlaxoSmithKline) | 3/5 (60%) | 0/2 (0%) | Rosiglitazone: GlaxoSmithKline (Avandia)  | Metformin: generic | Yes | No |
| Jadzinsky 2009 | Diabetes, Obesity and Metabolism | Bristol-Myers Squibb | 3/6 (50%) | 3/3 (100%) | Saxagliptin: Bristol-Myers Squibb (Onglyza) | Metformin: generic | Yes | Yes |
| Kaku 2009 | Current Med Res and opinion | Takeda Pharmaceutical Co | 0/1 (0%) | 0/1 (0%) | Combination therapy: Pioglitazone: Takeda Pharmaceuticals; Metformin: generic  | Metformin: generic | Yes | Yes |
| Nauck 2007; Seck 2010 | Diabetes, Obesity and Metabolism | Nauck: Merck & Co., Inc.Seck: Merck & Co., Inc. | Nauck: 4/5 (80%)Seck: 7/8 (86%) | Nauck: 1/1 (100%)Seck: 1/1 (100%) | Nauck: sitagliptin: MerckSeck: sitagliptin: Merck | Nauck: glipizide: genericSeck: glipizide: generic | Nauck: YesSeck: No | Nauck: NoSeck: Yes |
| Nauck 2009 | Diabetes Care | NR | 2/9 (22%) | 2/7 (29%) | Liraglutide: Novo Nordisk | Glimepiride: generic Amaryl: sanofi-aventisMetformin: generic | Yes | Yes |
| Perez 2009 | Current Med Res and opinion | Takeda Global Research and Development Center | 3/4 (75%) | 1/1 (100%) | Pioglitazone: Takeda Pharmaceuticals | Metformin: generic | Yes  | Yes  |
| Pratley 2010 | Lancet | NovoNordisk | 2/9 (22%) | 7/7 (100%) | Liraglutide: Novo Nordisk Pharmaceuticals Sitagliptin: Merck & Co | Metformin: generic | Yes | Yes |
| Raskin 2009 | Diabetes, Obesity and Metabolism | Novo Nordisk | 2/4 (50%) | 2/2 (100%) | Repaglinide: Novo Nordisk (Prandin) Metformin: generic | Rosiglitazone: GlaxoSmithKline Metformin: generic | Yes | No |
| Raz 2008 | Current Med Res and opinion | Merck & Co, USA | 8/9 (89%) | 0/1 (0%) | Sitagliptin: Merck & Co., Inc | Metformin: generic | NR | No |
| Rigby 2009 | Endocrine Practice | Daiichi Sankyo, Inc. | 4/6 (66%) | 1/2 (50%) | Colesevelam: Daiichi Sankyo (Welcho); Rosiglitazone: GlaxoSmithKline (Avandia); Sitagliptin: Merck & Co., Inc. | Metformin: generic | Yes | No |
| Robbins 2007 | Clinical Therapeutics | NR (clearly Eli Lilly) | 5/10 (50%) | 3/5 (60%) | Insulin lispro protamine: Eli LillyMetformin: generic | Insulin glargine: sanofi-aventis Metformin: generic | No | Yes |
| Rosenstock 2006 | Diabetes, Obesity and Metabolism | GlaxoSmithKline | 4/6 (66%) | 0/2 (0%) | Rosiglitazone/ metformin combination therapy: GlaxoSmithKline (Avandamet) | Rosiglitazone: GlaxoSmithKline (Avandia)Metformin: generic | Yes | No |
| Scott 2008 | Diabetes, Obesity and Metabolism | Merck & Co., Inc. | 3/4 (75%) | 0/1 (0%) | Sitagliptin: Merck & Co., Inc.Rosiglitazone: GlaxoSmithKline | Metformin: generic | NR | Yes |
| Seino 2010 | Current Med Res and opinion | Novo Nordisk Pharma Ltd, Japan | 2/4 (50%) | 2/2 (100%) | Liraglutide: Novo Nordisk (Victoza) | Glibenclamide: Taisho Pharmaceutical Co. | Yes | Yes |
| van der Meer 2009 | Circulation | This investigator-initiated study was supported by Eli Lilly, the Netherlands, which has a partnership with Takeda, the manufacturer of pioglitazone. Metformin tablets and matching placebos were kindly provided by Merck, the Netherlands. | 1/14 (7%) | 2/13 (15%) | Pioglitazone: Takeda Pharmaceuticals (Actos) | Metformin: generic | NR | Yes |